Evidence map›Paper›PMID 35148782›Full record

ArticleAIDS research and therapy2022

Clinical outcomes after IL-6 blockade in patients with COVID-19 and HIV: a case series.

Samuel J Minkove, Grant Geiger, Josep M Llibre, Mary W Montgomery, Natalie E West, Natasha M Chida, Annukka A R Antar, Dima Dandachi, Ethel D Weld, HIV-COVID-19 Consortium

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in AIDS research and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Samuel J Minkove *Department of Medicine, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Osler 508, Baltimore, MD, 21287, USA.
Grant GeigerUniversity of Missouri-Columbia School of Medicine, Columbia, USA.
Josep M LlibreInfectious Diseases and Fight AIDS Foundation, University Hospital Germans Trias, Badalona, Spain.
Mary W MontgomeryDepartment of Infectious Diseases, Brigham and Women's Hospital, Boston, USA.
Natalie E WestDepartment of Medicine, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Osler 508, Baltimore, MD, 21287, USA.
Natasha M ChidaDepartment of Medicine, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Osler 508, Baltimore, MD, 21287, USA.
Annukka A R Antar *Department of Medicine, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Osler 508, Baltimore, MD, 21287, USA.
Dima Dandachi *Department of Medicine, University of Missouri, Columbia, USA.
Ethel D Weld *Department of Medicine, The Johns Hopkins University School of Medicine, 600 N. Wolfe Street, Osler 508, Baltimore, MD, 21287, USA. eweld@jhmi.edu.
HIV-COVID-19 Consortium
Johns Hopkins Medicine · USUniversity of Missouri · USJohns Hopkins University · USBrigham and Women's Hospital · USFundació Lluita contra les Infeccions · ESNational Institutes of Health · US

Funding

Vaccine Response and Immunotherapeutics SWGP30AI094189 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Anna Palmer Durbin · 2012 to 2026
$67.0M
NIAID NIH HHS P30 AI094189
6 · The paper itself

Abstract

backgroundIn hospitalized people with HIV (PWH) there is an increased risk of mortality from COVID-19 among hospitalized PWH as compared to HIV-negative individuals. Evidence suggests that tocilizumab-a humanized monoclonal interleukin (IL)-6 receptor inhibitor (IL-6ri) antibody-has a modest mortality benefit when combined with corticosteroids in select hospitalized COVID-19 patients who are severely ill. Data on clinical outcomes after tocilizumab use in PWH with severe COVID-19 are lacking. CASE PRESENTATION: We present a multinational case series of 18 PWH with COVID-19 who were treated with IL-6ri's during the period from April to June 2020. Four patients received tocilizumab, six sarilumab, and eight received an undocumented IL-6ri. Of the 18 patients in the series, 4 (22%) had CD4 counts < 200 cells/mm

conclusionsIn this case series of hospitalized PWH with COVID-19 and given IL-6ri prior to the common use of corticosteroids, there are reports of secondary or co-infection in severely ill patients. Comprehensive studies in PWH, particularly with CD4 counts < 200 cells, are warranted to assess infectious and other outcomes after IL-6ri use, particularly in the context of co-administered corticosteroids.

Indexed as

COVID-19 Drug TreatmentHIV InfectionsHospitalizationHumansReceptors, Interleukin-6SARS-CoV-2Receptors, Interleukin-6

Identifiers

PMID35148782
PMCPMC8832430
OpenAlexW4211005104

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.